MBRX 10-Q: SEC filing
Moleculin Biotech
Filed with the SEC on · accession 0001437749-26-036901
MBRX filed a 10-Q (quarterly report) with the SEC on Nov 13, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -3.0% by the first close after the filing.
Summary of the filing
Moleculin Biotech filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosing a subsequent reverse stock split effective October 20, 2026, along with details of its August 2026 public offering of pre-funded and Series I warrants.
Key details
How MBRX stock reacted
Close before
$8.06
Nov 12, 2026
First close after
-2.98%
$7.82
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for MBRX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for MBRX?
Click hereFrequently asked questions
What did MBRX file with the SEC on Nov 13, 2026?
MBRX filed a 10-Q (SEC filing). Moleculin Biotech filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosing a subsequent reverse stock split effective October 20, 2026, along with details of its August 2026 public offering of pre-funded and Series I warrants.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did MBRX stock react to this filing?
MBRX closed at $8.06 before the filing and $7.82 on Nov 13, 2026 (-2.98%).
Other MBRX SEC filings
Get alerts when MBRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days